NYSEARCA:TMBR
Delisted
Timber Pharmaceuticals Inc Stock News
$0.343
+0 (+0%)
At Close: Feb 27, 2024
Timber Pharmaceuticals' Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer® (TMB-002) in Europe
08:00am, Wednesday, 17'th Mar 2021
- Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe -
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
08:30am, Monday, 15'th Mar 2021
- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder
TMBR Stock Price Increased 71.14%: What You Should Know About The Company
06:09pm, Thursday, 11'th Mar 2021
The stock price of Timber Pharmaceuticals Inc (NYSEAMERICAN: TMBR) increased by 71.14% today. This is what you should know about the company.
TMBR Stock: What to Know About Red-Hot Timber Pharmaceuticals
04:45pm, Thursday, 11'th Mar 2021
Timber Pharmaceuticals spiked more than 75% in trading today following a virtual life sciences conference this week. Trading volume in TMBR stock was up more than 1600% on the day.
Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
08:30am, Friday, 05'th Mar 2021
WOODCLIFF LAKE, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on
7 Penny Stocks In a Make-or-Break Year
01:07pm, Wednesday, 24'th Feb 2021
These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development. The post 7 Penny Stocks In a Make-or-Break Year appeared first
Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer
04:05pm, Monday, 25'th Jan 2021
Dr. Mendelsohn has 20+ Years' Experience in Clinical Development and Medical Affairs
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Sclerosis
04:22pm, Tuesday, 12'th Jan 2021
Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022
Timber Pharmaceuticals Hosts Business Update Conference Call
08:30am, Thursday, 10'th Dec 2020
Call to be held on Thursday, December 17th at 11:00am EST
